INTRODUCTION
The liver is the most common site of metastatic involvement in patients with neuroendocrine tumors (NETs). 1 Surgical resection is considered the standard of care for NET liver metastases, but the majority of patients have multifocal or extrahepatic disease, which makes surgery less desirable. Other treatments include octreotide analogues, 2, 3 ablative therapies, transcatheter arterial embolization (including radioembolization), peptide receptor radionuclide therapy, 4 systemic chemotherapy, [5] [6] [7] and targeted agents such as everolimus [8] [9] [10] [11] and sunitinib. 12 Somatostatin receptors (SSTRs) are strongly expressed in gastroenteropancreatic NETs. 13, 14 Pasireotide (SOM230) is a somatostatin analogue with an affinity for 4 of 5 SSTRs (SSTR1, SSTR2, SSTR3, and SSTR5). 15 Compared with octreotide acetate, pasireotide exhibits a binding affinity 30 to 40 times higher for SSTR1 and SSTR5, 5 times higher for SSTR3, and 2.5 times lower for SSTR2. Safety and efficacy data are available from a phase 2 study of patients with symptomatic metastatic carcinoid disease. Pasireotide was generally well tolerated, with the most common adverse events being hyperglycemia, mild diarrhea, weight loss, nausea, and abdominal pain. Efficacy data show partial or complete symptom control in NET patients with disease refractory/resistant to long-acting octreotide. 16 In another study, pasireotide controlled carcinoid-associated symptoms in 25% of octreotide-refractory patients. 17 Everolimus is a selective inhibitor of mammalian target of rapamycin (mTOR), which is downstream of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. As part of the mammalian target of rapamycin complex 1 (mTORC1) signaling complex, mTOR plays a central role in tumor cell growth, proliferation, and angiogenesis via activation of tumor-cell hypoxia-inducible factor 1 and vascular endothelial growth factor. 18, 19 A negative mTORC1/Akt feedback loop increases Akt activity and contributes to resistance to mTOR inhibition. 20, 21 Somatostatin analogues have been shown to decrease PI3K/Akt signaling. [21] [22] [23] [24] In pituitary tumor cells, octreotide reverses a rapamycin-induced increase in Akt phosphorylation, which is an important mechanism of resistance. 25 A phase 1 trial showed the safety of longacting intramuscular pasireotide (60 mg monthly) in combination with everolimus (10 mg daily). The doselimiting toxicities (DLTs) were grade 3 rash and diarrhea; hyperglycemia was commonly observed (38.1%). 26 Selective internal radioembolization (SIRT) has been shown to be effective in the treatment of NET patients with symptomatic liver involvement. 27, 28 NET liver metastases are highly vascularized and derive their blood supply from the hepatic artery. 29 SIRT embolizes radioactive yttrium-90 microspheres into a branch of the hepatic artery lodging in the tumor precapillary vasculature 30, 31 ; it delivers a high dose of ionizing radiation to the tumor and spares the liver parenchyma. Data supporting SIRT treatment for NETs mainly are derived from retrospective institutional series demonstrating safety, symptom control, and biochemical responses. [32] [33] [34] Response and symptom-control rates have ranged from 22% to 64%, and the most commonly observed toxicity has been fatigue. The efficacy and toxicity of the 2 kinds of microspheres in clinical practice, TheraSphere and SIR-Spheres, have not been compared in NETs. One mechanism of resistance to the embolic effects of SIRT is hypoxia-driven production of angiogenic factors and revascularization of the tumor. mTOR has a central role in the transcription of these angiogenic cytokines. Persistent activation of the mTOR signaling pathway has been shown to contribute to radioresistance. 35 On the basis of these data, we hypothesized that the combination of pasireotide and everolimus would optimize inhibition of the mTOR signaling pathways by inhibiting crosstalk between the somatostatin receptor (SSR) signaling pathway and mTORC. Furthermore, this combination would potentiate the embolic effects of SIRT by inhibiting the rebound production of angiogenic factors and improve the sensitivity to radiation delivered through SIRT. The main clinical concern with using this combination is the potential for everolimus and pasireotide to increase hepatic injury from SIRT. We, therefore, conducted this phase 1 trial.
MATERIALS AND METHODS

Patient Selection
The study was approved by the institutional review board at Emory University and was registered with ClinicalTrials.-gov (NCT01469572). Written consent was obtained from all patients before enrollment. The inclusion criteria were as follows: age 18 years, stage IV well-differentiated or moderately differentiated NETs with measurable disease and unresectable bilobar hepatic metastases, disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) on long-acting octreotide (30 mg monthly), Eastern Cooperative Oncology Group performance status 2, hemoglobin A 1 C level < 7%, adequate bone marrow (absolute neutrophil count > 1500/cc and platelet count > 100,000/cc) and renal function (creatinine level 1.5 mg/dL), tumor volume < 50% of the total liver, bilirubin level < 3 mg/dL, alanine transaminase level < 3 times the upper limit of normal, and international normalized ratio 1.5. Prior systemic therapy (2 prior lines, excluding mTOR inhibitors), surgery, and radiation were allowed. The washout period for systemic therapy was 4 weeks. Patients had to have evidence of disease progression by RECIST (version 1.1) despite optimal octreotide therapy (equivalent to 30 mg of octreotide long-acting repeatable every month). Prior radiation to the abdomen was not allowed.
Exclusion criteria included the following: chronic liver disease such as cirrhosis or severe hepatic impairment; evidence of ascites, portal hypertension, or portal vein thrombosis; contraindications to angiography; active bleeding diathesis (excluding therapeutic anticoagulation); chronic systemic treatment with corticosteroids or immunosuppressive agents; immunocompromised status; uncontrolled brain or leptomeningeal metastases; other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin; uncontrolled medical conditions; and impairment of gastrointestinal function affecting the absorption of everolimus.
Study Design
This phase 1b study followed a standard 3 1 3 doseescalation design. The primary objective was to determine the recommended phase 2 dose (R2PD) of everolimus in combination with pasireotide and SIRT. The dose of pasireotide was fixed at 600 lg subcutaneously administered by patients twice daily. Three dose levels of everolimus were evaluated: 2.5, 5, and 10 mg by mouth daily. Pasireotide and everolimus administration started 9 days before SIRT to allow everolimus to achieve a steady state. 36 SIRT was administered to the first lobe on day 9 and to the second lobe on day 37. If there were no ongoing toxicities, 4 weeks after the second SIRT treatment, patients began a maintenance phase with everolimus (10 mg daily) and long-acting pasireotide (60 mg every month). Figure 1 presents a schema of the trial design. Cross-sectional imaging was performed at the baseline and every third cycle (each cycle was 28 days). Because of the high risk of hyperglycemia with pasireotide and everolimus, guidelines for monitoring and managing hyperglycemia were clearly defined, as detailed in the online supporting information.
SIRT was performed with the standard dosing regimen for SIR-Spheres, as detailed in the online supporting information. The actual dose was calculated as follows:
(Body surface area -0.2) 1 (Tumor involvement/100)
The endpoint of the injection was either the entire calculated and supplied dose being delivered (0.740-2.220 GBq per lobe treated) or vascular flow stasis being reached.
Outcome Assessment
A DLT was defined as suspected treatment-related toxicity observed in the 28 days after the completion of the first SIRT treatment. DLTs had to meet the following criteria: a grade 4 hematologic toxicity lasting 7 or more days, a grade 3 nonhematologic toxicity lasting 7 or more days, or a grade 4 nonhematologic toxicity of any duration. The R2PD was considered the dose level below the dose level at which at least 2 of 6 patients would develop a DLT. The secondary objectives were to evaluate toxicities, response rates (measured with RECIST), progression-free survival (PFS), overall survival (OS), and changes in chromogranin A levels, insulin-like growth factor 1 (IGF-1), and other angiogenic and apoptotic markers.
Quality of Life (QOL)
The Norfolk Quality of Life-Neuroendocrine Tumor Questionnaire (QOL-NET) module 37 was administered at the baseline and every 28 days. QOL-NET is a standardized, self-administered questionnaire designed to capture and quantify the QOL of patients with NETs. The questionnaire consists of 72 numbered items based on particular functions or symptoms related to the following themes: symptom frequency, symptom severity, activities of daily life, and feelings.
Correlative Assays
As described in the online supporting information, markers of angiogenesis (soluble vascular endothelial growth factor receptor 2, basic fibroblast growth factor, placenta growth factor, interleukin 8, collagen IV, and angiopoietin 1/2), tumor apoptosis and necrosis (M30 and M65), and insulin growth factors (IGF-1, IGF-2, and IGF-binding proteins), were assessed in samples collected at the baseline, on day 8, and on day 9. Levels of prolactin, growth hormone, and chromogranin A were assessed at the baseline and at 3 months.
Statistical Analyses
Kaplan-Meier survival curves and log-rank tests were used to explore the association of each covariate with PFS, which was defined as the time from the start of treatment until disease progression or death as a result of any cause. OS was defined as the time from the start of treatment until death as a result of any cause, with patients censored at the date of last follow-up if they were still alive. Significance levels were set at .05 for all tests. The SAS statistical package (version 9.4; SAS Institute, Inc, Cary, North Carolina) was used for all data management and analyses. Statistical analyses for biomarker and QOL data are detailed in the online supporting information. Figure 1 . Schema of the clinical trial in the dose-escalation and maintenance phases. D1 indicates day 1; D9, day 9; D37, day 37; D57, day 57; E, everolimus (10 mg by mouth daily) in the maintenance phase of the trial; P l , pasireotide (60-mg long-acting dose once every 28 days); P s 1e, short-acting pasireotide (600lg subcutaneously twice daily) concurrently with everolimus (dose based on the dose level defined in phase 1b); Y-90; selective radioembolization (yttrium-90) delivered on days 9 and 37 to both liver lobes interchangeably.
RESULTS
Treatment
Thirteen patients were enrolled between June 2012 and August 2014. Table 1 describes the patients' baseline characteristics. Three patients were enrolled on dose level 1, 3 patients were enrolled on dose level 2, and 7 patients were enrolled on dose level 3. Twelve patients completed the first SIRT treatment (1 developed a reaction to the first dose of pasireotide and was not evaluable for the primary endpoint), and 11 completed the second. One patient had limited disease in a partially resected left lobe, and a clinical decision was made not to treat the left lobe. Three patients had disease progression after the completion of SIRT (in an extrahepatic site in 2 patients) and did not receive maintenance therapy. One patient remained on active therapy.
Toxicity
No DLTs were observed, no patients required hospitalization, and there were no treatment-related deaths. The most common toxicities during the first 28 days were hyperglycemia and hematologic toxicities ( Table 2) . Suspected treatment-related adverse events across all treatment cycles were consistent with the expected toxicities of both everolimus and pasireotide. Treatment-related adverse events included hyperglycemia. The average hemoglobin A 1C level was 5.7% at the baseline and 7.7% at 3 months. Liver toxicity, as reflected by alterations in liver function tests, was mild and reversible. The most commonly observed toxicities beyond the first 28 days included hyperglycemia, grade 1 liver toxicities, hematologic toxicities, weight loss, fatigue, and dysgeusia (Table  2) . Liver toxicities, weight loss, and fatigue were attributed to SIRT side effects. No clinical signs or symptoms of liver failure were seen during the trial.
Response and Survival Outcomes
Six of the 13 patients (46%) had partial radiographic response, 3 had stable disease, and 3 had progression of the disease as their best response. The median PFS was 18.6 months (95% confidence interval, 7.3 months to not reached); the PFS rates were 61.5% at 1 year, 46.2% at 2 years, and 38.5% at 3 years ( Fig. 2A) . Four patients (30.8%) had no progression when the study was analyzed. The median OS was 46.3 months (95% confidence interval, 18 months to not reached); the OS rates were 92.3% at 1 year, 69.2% at 2 years, and 61.5% at 3 years (Fig.  2B ).
QOL Results
QOL is an important endpoint in clinical research trials, particularly phase 1 trials. Significant improvements in QOL measures were observed over days during the trial in the categories of depression, physical functioning, and positive attitude (Fig. 3) . These measures reflect symptom control (frequency and severity), activities of daily living, and general feelings during the period of the trial. The significance of QOL results is limited by the small sample size.
Correlative Serum Markers
Significant decreases in the serum levels of angiopoietin 1 and fibroblast growth factor were observed between the baseline and day 8 ( Supporting Fig. 1A,B [see online supporting information]). No significant increase in any circulating markers of angiogenesis was seen after SIRT. No significant changes in M30 or M65 levels were observed between the baseline, day 8, and day 9 (ie, after SIRT). 
Original Article
This further confirms that the treatment combination resulted in a limited, mild acute injury to the liver (Supporting Table 1 [see online supporting information]). No significant difference was observed between the baseline and 3-month levels of hepatocyte growth factor (HGF) or prolactin. At baseline and 3 months, the mean hepatocyte growth factor levels were 0.6 and 0.57 ng/mL, respectively (paired t test P 5 .85); the mean prolactin levels were 8.2 and 6.9 ng/mL, respectively (P 5 .28); and the mean chromogranin A levels were 3178 and 6638 ng/mL, respectively (P 5 .43).
DISCUSSION
The combination of pasireotide, everolimus, and SIRT is well tolerated with an acceptable toxicity profile. The R2PD in combination with SIR-Spheres radioembolization is everolimus at 10 mg daily and pasireotide at 600 lg twice daily. A safety concern when the trial was being planned was whether everolimus would increase the frequency of acute or chronic liver injury in patients with NETs receiving SIRT. The patients enrolled in this study had bilobar liver disease, and a considerable number had received prior liver-directed therapies such as resection or ablation. Even with this profile, the regimen had limited, low-grade, reversible liver toxicity. There was no evidence of acute liver injury after SIRT from liver function tests or markers of tissue apoptosis (M30 or M65 levels). More importantly, we did not observe any significant changes in liver function tests in any of the patients even with longterm follow-up. Besides hyperglycemia, hematologic and nonhematologic toxicities observed in this trial were within the expected profile and the previously reported frequencies.
Hyperglycemia was the most common side effect observed in this trial. The increased incidence of hyperglycemia among patients receiving single-agent pasireotide has been reported to be 28.3% with all grades 38 and 9.4% with grade 3 or 4 toxicity. There is also an increased risk of hyperglycemia with single-agent everolimus. 39 The phase 2 Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET (COOPERATE-2) study of pasireotide and everolimus showed an incidence of grade 3 or 4 hyperglycemia of 37%. 40 In our study, grade 3 hyperglycemia occurred in 5 patients (38.5%). Pasireotide did not significantly increase growth hormone levels. Hyperglycemia was highest in patients receiving dose level 3, and this suggests a role for everolimus. Only 1 patient discontinued the trial because of hyperglycemia. The limited clinical impact of hyperglycemia is due to a clearly defined plan for the monitoring and management of glucose levels. The monitoring and management of hyperglycemia were Liver metastases are a dominant cause of treatment failure in NET patients. 27, 28 SIRT has shown response rates in the range of 22% to 64%, and this is more pronounced in patients with symptomatic carcinoid syndrome in liver-dominant NETs. 27 Data regarding the activity of SIRT in NET liver metastases are largely based on retrospective, single-institution series. Response rates from approved targeted systemic treatments such as everolimus are in the range of 5%.
9,41 PFS observed with single-agent everolimus for advanced-stage NETs is approximately 11 months. 9, 10 In the Neuroendocrine Tumors Therapy (NETTER-1) trial, peptide receptor radionuclide therapy showed an impressive median PFS of approximately 40 months with systemic disease control and disease control in the liver in select patients with SSTR expression by scintigraphy. 42 The patients in our trial had several poor prognostic features, including bilobar liver disease and progression on high-dose octreotide analogues, and a large proportion had extrahepatic disease and multiple prior liver-directed therapies. The combination of a somatostatin analogue (pasireotide), an mTOR inhibitor (everolimus), and SIRT showed a median PFS of 18.6 months and a response rate of 40%. Local control of disease in the liver was excellent, with the majority of disease progression occurring at extrahepatic sites. Furthermore, this treatment did not have a negative impact on QOL. Because of this trial's design, the benefit of adding everolimus to SIRT cannot be determined, and this would need to be evaluated prospectively in a randomized trial. In conclusion, pasireotide with everolimus (10 mg daily) can be safely administered with SIRSpheres in patients with NET liver metastases. On the basis of the results of this trial, a continued evaluation of the everolimus and SIRT combination is warranted. A randomized trial comparing this combination with the standard of care of everolimus in NET patients with predominant liver metastases is needed to confirm the role of combination therapy in this setting. Patients whose tumors are not avid on SSTR scintigraphy have limited options at the time of progression on a somatostatin receptor analogue and may be candidates for such a trial.
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